Pfizer (PFE) Raw Materials (2009 - 2019)

Pfizer has disclosed Raw Materials across 11 years of filings, most recently posting $560.0 million for Q1 2019.

• In Q1 2019, Raw Materials fell 32.12% year-over-year to $560.0 million; the TTM figure through Mar 2019 stood at $560.0 million (down 32.12% YoY), while the FY2018 annual figure was $546.0 million, down 30.71% from the prior year.
• Raw Materials grew to $560.0 million in Q1 2019, from $546.0 million in the prior quarter.
• Over the last five years, Raw Materials for PFE reached as high as $950.0 million in Q3 2016 and fell as low as $475.0 million in Q1 2015.
• The 5-year median for Raw Materials is $809.0 million (2016), against an average of $754.1 million.
• Annual changes were most pronounced in 2016 — Raw Materials surged 84.82% — and 2019, when it slumped 32.12%.
• A 5-year view of Raw Materials shows it stood at $867.0 million in 2015, then decreased by 8.54% to $793.0 million in 2016, then declined by 0.63% to $788.0 million in 2017, then sank by 30.71% to $546.0 million in 2018, then advanced by 2.56% to $560.0 million in 2019.
• According to Business Quant data, Raw Materials over the past three periods registered $560.0 million, $546.0 million, and $839.0 million for Q1 2019, Q4 2018, and Q3 2018 respectively.